Cytori (NASDAQ: CYTX) received its first order from Green Hospital
Supply for a StemSource®
Cell Bank, which will be installed in one of the leading public
universities in Japan.
This is an important development for Cytori, as the cell bank will be
installed at a prestigious academic hospital and will have significant
visibility in the Japanese market. The size and geographic reach of the
hospital will benefit a large population of patients. In addition, the
hospital’s well known reputation for research
and patient care should facilitate additional StemSource Cell Bank sales
among other prospective hospital customers in Japan.
A StemSource Cell Bank is the key to allowing hospitals to process and
cryopreserve a patient’s own adipose-derived
stem and regenerative cells, when the cells are younger and more viable.
StemSource Cell Banking services coupled with the real time Celution
clinical cell therapy which is now under clinical evaluation in centers
throughout the world would ultimately allow hospitals to provide a broad
array of regenerative medicine services to patients and will
differentiate them from other health care providers.
The foundation of the cell bank is Cytori’s
Celution® 900-MB
System, which automates the processing of stem and regenerative cells
from adipose tissue. This function facilitates the preparation and
storage of the cells, thereby creating economic and process efficiencies
that would otherwise make cell banking too expensive or time consuming.
The StemSource Cell Bank is being marketed on Cytori’s
behalf to hospitals in Japan, Korea, Taiwan and Thailand exclusively by
Green Hospital Supply (GHS). The identity of the first banking customer
will be publicly disclosed soon in deference to the formal announcement
by the hospital itself and Green Hospital Supply. In addition, Cytori is
commercializing the StemSource® Cell Bank
directly in Europe, the Middle East and additional countries in Asia.
About Cytori
Cytori's (NASDAQ: CYTX) goal is to be the global leader in regenerative
medicine. The company is dedicated to providing patients with new
options for reconstructive surgery, developing treatments for
cardiovascular disease, and banking patients' adult stem and
regenerative cells. The Celution®
800 System is being introduced in Europe into the reconstructive surgery
market while the Celution®
900 System is being commercialized globally for cryopreserving a
patient's own stem and regenerative cells. Clinical trials are ongoing
in cardiovascular disease and planned for spinal disc degeneration,
gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include our
history of operating losses, the need for further financing, regulatory
uncertainties regarding the collection and results of, clinical data,
dependence on third party performance, and other risks and uncertainties
described under the "Risk Factors" in Cytori's Securities and Exchange
Commission Filings. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances
after the date they are made.
Media & Investor Contact:
Cytori Therapeutics
Tom
Baker, 858-875-5258
tbaker@cytoritx.com
